WebSo we’re talking with Celine Halioua, the founder and CEO of Loyal, a biotech start-up with a mission to extend a dog’s lifespan. She believes that if they’re successful, it could work on humans too. Jon and Celine talk about Silicon Valley culture and ask the big tech question: Just because we can do something, should we? WebOct 13, 2024 · People have been searching for a fountain of youth for thousands of years. Celine Halioua thinks she’s found one—for canines. Be patient, we’re next.
My Flaws — Celine Halioua
WebCeline Halioua. Hi, I’m Celine. I am the founder and CEO of Loyal, a biotech startup developing drugs to extend dog lifespan. I also dabble in biotech & deep-tech investing. WebJun 16, 2024 · We talk with Celine Halioua, founder and CEO of Loyal — a startup that is developing drugs to extend dog lifespan. Celine was in the second cohort of the On Deck Founder fellowship and recently announced an $11M raise — one of the largest seed rounds ever for a female solo founder. isaiah 53 aaron shust chords
Loyal, la start-up qui veut prolonger la vie Flipboard
WebAug 12, 2024 · Celine Halioua, founder and Chief Executive Officer for biotech startup company Loyal, which is focused on the development of drugs to prolong dogs’ lifespans, wrote in a blog post on Wednesday that de Grey previously made inappropriate comments to her during her time as an intern at SENS back in 2016. WebCeline Halioua A few thoughts on choosing which disease to develop a drug for. Generally speaking, there are at least three approaches to developing new drugs: Disease-first: you start with the disease and try to find drugs against new or known molecular targets that are relevant to that specific disease . Pathway-first: ... WebJul 6, 2024 · A second drug, aimed at "doggy dementia" and chronic kidney disease, also is expected to start a study in dogs this year. Cellular Longevity Inc. — or Loyal, as the 30 … isaiah 53 activities for kids